China Life Science and Technology Innovation Fund
国寿科创基金
The China Life Science and Technology Innovation Fund (国寿科创基金) is a fund affiliated with China Life Insurance (中国人寿), participating as a co-investor in venture rounds for hard-tech and life-science companies. Per 5Y Capital's reporting, it followed on in Yanming Biotech's RMB 700 million Series A in 2023 alongside China Venture Capital (国投创业), Taiping Healthcare Fund, and others , and also joined Vastai Technologies' RMB 1.6 billion Series B-1/B-2 in late 2021 as a co-investor with Alibaba, PICC Capital, and 5Y Capital itself . elsewhere's corpus does not contain further detail on its vintage, AUM, or dedicated investment thesis.
AI-generated — may contain errors, please verify.
Coverage
Autumn's Prime: Six FreeS Fund Early-Stage Portfolio Companies Raise Nearly 1 Billion RMB | FreeS Family Funding News Vol.15
Looking forward to working alongside more outstanding founders.
2022, the Door Opens to the Future | 5Y News Monthly
The big news from last month.
5Y News | Vastai Technologies Completes Two Consecutive Rounds of Series B-1 and B-2 Funding, Raising 1.6 Billion RMB
5Y Capital has been closely following the development of China's AI sector.
